Blood-Brain Barrier (BBB) Delivery Technology Platform

The BBB-Delivery™ platform unlocks CNS drug potential by integrating diverse RMT pathways for optimal brain delivery.

Powering Next-Generation CNS Therapeutics

The blood-brain barrier (BBB) is a major obstacle preventing large-molecule drugs (such as antibodies, enzymes, and proteins) from entering the central nervous system to treat diseases. Leveraging cutting-edge technology and a dedicated team, Protheragen has developed the BBB-Delivery™ platform, designed to overcome the challenges of neurological drug development by providing diverse receptor-mediated transcytosis (RMT) technologies, such as TfR, CD98hc, dual-targeting, and IGF1R shuttle systems. This modular approach allows us to tailor optimal delivery strategies for your specific therapeutic, ensuring efficient penetration of the blood-brain barrier and targeted action. From initial shuttle selection and molecular design to comprehensive preclinical validation, our platform offers an end-to-end solution designed to reduce development risk, accelerate progress, and translate promising compounds into viable central nervous system (CNS) therapies.

Introduction to Blood-Brain Barrier (BBB)

The blood-brain barrier (BBB) is a highly selective, protective shield that precisely regulates the exchange between the bloodstream and the central nervous system (CNS). While essential for maintaining brain homeostasis, this intricate biological fortress presents an almost insurmountable obstacle for drug delivery, effectively blocking over 98% of all potential CNS therapeutics and leaving a vast landscape of neurological diseases inadequately treated.

Physiological Exclusion Mechanisms
Species-Specific Translational Hurdles
Dynamic and Selective Barrier Nature

The Bottleneck of Current Biologics

The development of effective large-molecule therapeutics for central nervous system (CNS) disorders, such as monoclonal antibodies, remains fundamentally constrained by the blood-brain barrier (BBB). The extremely low brain bioavailability of these drugs forces the administration of high systemic doses to achieve minimal therapeutic effects in the brain. This paradigm leads to suboptimal efficacy, significant safety risks, high treatment burden, and has contributed to the failure or market withdrawal of numerous drug candidates.

Drug Names	Targets	Indications	Research Phase	Key Limitations & BBB Challenge
Lecanemab	Amyloid-β	Alzheimer's Disease	Approved	Extremely low brain uptake (<0.1%). Requires high-dose, bi-weekly IV infusions, leading to significant safety risks like ARIA (amyloid-related imaging abnormalities).
Donanemab	Amyloid-β	Alzheimer's Disease	Approved	Similar poor BBB penetration necessitates high dosing and carries ARIA risks. Its approval underscores the high unmet need despite delivery limitations.
Aducanumab	Amyloid-β	Alzheimer's Disease	Approved then withdrawn	Inconsistent efficacy and safety profile directly linked to the challenge of achieving sufficient brain levels without toxic systemic exposure, leading to its market withdrawal.
Bapineuzumab, Solanezumab	Amyloid-β	Alzheimer's Disease	Phase III (Terminated)	Multiple high-profile clinical trial failures due to inability to demonstrate clear cognitive benefit, attributed to insufficient drug delivery to relevant brain targets.
Cinpanemab, Prasinezumab	α-Synuclein	Parkinson's Disease	Phase II (Terminated)	Failed to meet primary endpoints in Parkinson's disease trials. Highlights the BBB delivery barrier extending beyond Alzheimer's to other neurodegenerative diseases.

BBB-Delivery™ Platform: Integrating Diverse RMT Pathways

Transferrin Receptor (TfR) Shuttle
CD98hc (LAT-1) Shuttle
TfR + CD98hc Dual-Targeting Shuttle
Insulin-like Growth Factor 1 Receptor (IGF1R) Shuttle

Protheragen’s TfR shuttle is a precision-engineered molecular vehicle designed to co-opt the brain’s natural iron-transport machinery. The platform is built on high-affinity, humanized antibody fragments or binding domains that specifically target the apical side of the brain endothelial cell’s transferrin receptor (TfR1). This binding mimics endogenous ligand-receptor interaction, initiating a clathrin-mediated endocytic process. Critically, our shuttle is engineered with pH-sensitive binding properties and optimal binding affinity (Kd) to ensure efficient release within the acidic endosomal compartment and subsequent transcytosis across the endothelial cell, rather than degradation in lysosomes. This results in the active, receptor-mediated transport of conjugated therapeutic cargo from the systemic circulation into the brain parenchyma.

Key Advantages and Applications

Key Advantages

Validated High Capacity: TfR is one of the most abundant and well-characterized RMT pathways, offering a robust and high-capacity route for brain delivery.
Rapid Brain Uptake: Facilitates swift transport, leading to high initial brain concentrations (Cmax), ideal for therapies requiring acute target engagement.
De-risked Developmental Path: As the most clinically advanced RMT approach, it provides a strong foundation with extensive pharmacokinetic/pharmacodynamic (PK/PD) correlation data, reducing preclinical uncertainty and clarifying the path to clinical translation.

Application Areas

Enzyme Replacement Therapies (ERT) for Lysosomal Storage Disorders: Specifically engineered to deliver missing enzymes (e.g., iduronate-2-sulfatase for MPS II/Hunter syndrome) to the brain, addressing the central nervous system manifestations of these diseases.
Therapies Targeting Intracellular Neuronal Pathways: Ideal for cargoes designed to act within neurons, as the TfR pathway facilitates efficient endosomal internalization and subsequent intracellular release.
Programs Requiring Fast Proof-of-Concept: The ability to achieve high early brain exposure makes this shuttle an excellent choice for initial target validation and rapid efficacy readouts in preclinical development.

The CD98hc shuttle exploits a distinct receptor-mediated transcytosis (RMT) pathway by selectively targeting the CD98hc subunit of the LAT-1 transporter on brain endothelial cells. Unlike the TfR route, CD98hc engagement triggers a clathrin-independent internalization process that leads to altered intracellular vesicular trafficking. This results in prolonged residence within transcytotic vesicles and a characteristically slower, more sustained release of the therapeutic cargo into the brain parenchyma. This unique kinetic profile is engineered to maximize central nervous system exposure duration rather than peak concentration.

Key Advantages and Applications

Platform Profile	Description
Advantages	Extended Brain Retention & Sustained Exposure: This pathway is engineered for prolonged drug action within the brain, offering a significantly longer parenchymal half-life than TfR-mediated delivery. This enables sustained target coverage and supports less frequent dosing. Optimized PK/PD & Safety Profile: The shuttle is designed to achieve a superior brain-to-plasma AUC ratio, maximizing therapeutic exposure in the CNS while minimizing systemic circulation and peripheral off-target risks. Broad CNS Cellular Engagement: Post-transcytosis, the shuttle facilitates effective biodistribution to both neurons and key glial cells (astrocytes, microglia), making it ideal for therapies targeting neuroinflammation or glial-specific pathologies.
Applications	Chronic Therapies for Prolonged Target Occupancy: Optimized for continuous neutralization of targets like neurotoxic protein oligomers (α-synuclein, tau) or sustained antagonism of cell surface receptors in chronic CNS disorders. Sustained Modulation of Neuroinflammation: Ideal for delivering biologics that require durable engagement with astrocyte or microglial pathways to modify disease progression in conditions like multiple sclerosis or ALS. Extended Brain Exposure for Protein Therapeutics: Enables enzyme replacement or other protein therapies where maintaining prolonged, steady-state brain concentration is critical for efficacy and reduced dosing frequency.

Platform Profile

Description

Advantages

Extended Brain Retention & Sustained Exposure: This pathway is engineered for prolonged drug action within the brain, offering a significantly longer parenchymal half-life than TfR-mediated delivery. This enables sustained target coverage and supports less frequent dosing.
Optimized PK/PD & Safety Profile: The shuttle is designed to achieve a superior brain-to-plasma AUC ratio, maximizing therapeutic exposure in the CNS while minimizing systemic circulation and peripheral off-target risks.
Broad CNS Cellular Engagement: Post-transcytosis, the shuttle facilitates effective biodistribution to both neurons and key glial cells (astrocytes, microglia), making it ideal for therapies targeting neuroinflammation or glial-specific pathologies.

Applications

Chronic Therapies for Prolonged Target Occupancy: Optimized for continuous neutralization of targets like neurotoxic protein oligomers (α-synuclein, tau) or sustained antagonism of cell surface receptors in chronic CNS disorders.
Sustained Modulation of Neuroinflammation: Ideal for delivering biologics that require durable engagement with astrocyte or microglial pathways to modify disease progression in conditions like multiple sclerosis or ALS.
Extended Brain Exposure for Protein Therapeutics: Enables enzyme replacement or other protein therapies where maintaining prolonged, steady-state brain concentration is critical for efficacy and reduced dosing frequency.

Protheragen’s dual-targeting shuttle represents a proprietary, next-generation platform that coordinates the two most validated RMT pathways into a single bispecific molecule. Utilizing advanced protein engineering, this shuttle is designed to simultaneously and with optimized affinity engage both the TfR and the CD98hc (LAT-1) receptor on brain endothelial cells. This co-engagement orchestrates a complementary “Fast-Track & Park” mechanism: the high-capacity TfR pathway drives rapid initial internalization and transcytosis, while the CD98hc pathway concurrently guides the cargo into distinct intracellular vesicles that facilitate slower release and prolonged retention within the brain parenchyma. This results in a pharmacologically superior kinetic profile.

Key Advantages and Applications

Core Advantages

Synergistic PK Profile: Uniquely combines the rapid Cmax of TfR with the extended half-life and AUC of CD98hc, creating an optimal brain exposure curve unmatched by single shuttles.
Broadened Therapeutic Scope: Enables combined immediate and sustained intervention, ideal for complex, progressive diseases requiring multi-timepoint pharmacological action.
Proprietary & Optimized Design: Features an engineered asymmetric format that precisely balances receptor affinity and valency to maximize transcytosis efficiency while minimizing off-target clearance.

Ideal Applications

High-Efficacy Neurodegenerative Disease Programs: Specifically designed for Alzheimer’s and Parkinson’s disease, where maintaining supra-threshold drug levels against rapidly turning over pathogenic proteins is critical.
Disorders Requiring Acute & Chronic Control: Suited for conditions like refractory epilepsy or CNS malignancies that demand both rapid onset and sustained therapeutic effect.
Platform for Best-in-Class Candidates: The strategic choice for programs aiming to achieve superior efficacy and differentiation beyond conventional delivery modalities.

The IGF1R shuttle offers a strategically distinct entry point into the CNS by targeting the insulin-like growth factor 1 receptor, a tyrosine kinase receptor constitutively expressed at the blood-brain barrier. Unlike TfR and CD98hc, IGF1R engagement activates a unique endocytic pathway linked to distinct intracellular sorting signals. Our shuttle is built upon a high-affinity binding domain that is specifically optimized to potently engage the receptor's extracellular domain without inducing significant receptor activation or downstream signaling. This design ensures efficient clathrin-mediated internalization and transcytosis while preserving the physiological IGF-1/IGF1R axis, which is critical for normal neural function and development.

Key Advantages and Applications

Platform Profile	Description
Advantages	Distinct Targeting & Biodistribution: Exploits unique spatial expression of IGF1R for potential region-specific or cell-selective CNS delivery, offering a complementary route to TfR/CD98hc. Engineered Signaling Inertia: Designed as a high-affinity, non-agonistic ligand to enable efficient RMT while minimizing interference with the critical endogenous IGF-1 signaling pathway, enhancing safety. Strong Translational Predictability: Benefits from high evolutionary conservation of IGF1R across species, reducing PK/PD translation risks from preclinical models to human trials.
Applications	CNS Tumors: A targeted vehicle for delivering chemotherapeutics, tumor-specific antibodies, or immune modulators across both the BBB and the compromised blood-tumor barrier (BTB) into IGF1R-positive malignancies such as glioblastoma. Neurodegenerative Disorders: A strategic choice for diseases like Alzheimer's or ALS, where impaired IGF1R signaling is part of the pathology, allowing the shuttle to leverage this native biology for enhanced, targeted delivery to affected brain regions. Enzyme Related CNS Disorders: Enables efficient brain delivery of lysosomal enzymes or other therapeutic proteins for disorders with CNS involvement (e.g., certain lysosomal storage diseases), where sustained enzyme activity is required.

Platform Profile

Description

Advantages

Distinct Targeting & Biodistribution: Exploits unique spatial expression of IGF1R for potential region-specific or cell-selective CNS delivery, offering a complementary route to TfR/CD98hc.
Engineered Signaling Inertia: Designed as a high-affinity, non-agonistic ligand to enable efficient RMT while minimizing interference with the critical endogenous IGF-1 signaling pathway, enhancing safety.
Strong Translational Predictability: Benefits from high evolutionary conservation of IGF1R across species, reducing PK/PD translation risks from preclinical models to human trials.

Applications

CNS Tumors: A targeted vehicle for delivering chemotherapeutics, tumor-specific antibodies, or immune modulators across both the BBB and the compromised blood-tumor barrier (BTB) into IGF1R-positive malignancies such as glioblastoma.
Neurodegenerative Disorders: A strategic choice for diseases like Alzheimer's or ALS, where impaired IGF1R signaling is part of the pathology, allowing the shuttle to leverage this native biology for enhanced, targeted delivery to affected brain regions.
Enzyme Related CNS Disorders: Enables efficient brain delivery of lysosomal enzymes or other therapeutic proteins for disorders with CNS involvement (e.g., certain lysosomal storage diseases), where sustained enzyme activity is required.

Why Choose Us

Unlike single-pathway approaches, Protheragen's BBB-Delivery™ platform provides the industry's most comprehensive and modular suite of validated receptor-mediated transcytosis (RMT) shuttles, including TfR, CD98hc, dual-targeting, and IGF1R based solutions. We don't offer a one-size-fits-all answer; instead, we partner with you to strategically select and optimize the ideal shuttle based on your specific therapeutic's pharmacokinetic requirements, target engagement profile, and disease pathology. This integrated, data-driven platform de-risks CNS drug development by ensuring your biologic is equipped with the most efficient and tailored key to cross the blood-brain barrier.

Integrated BBB Expertise
Cutting-Edge Technology
Customized Service Workflow
End-to-End Solutions

FAQs

Q: How do you ensure the safety of your shuttles, particularly regarding receptor interference? A: Safety-by-design is a core principle. For example, our IGF1R shuttle is engineered as a high-affinity, non-agonistic ligand to minimize disruption of critical endogenous signaling. Across all shuttles, we meticulously optimize binding affinity and valency to promote efficient transcytosis while reducing the risk of on-target, off-brain effects and unwanted receptor modulation.
Q: Can your platform deliver different types of therapeutic cargo? A: Absolutely. Our shuttle technologies are modular and can be conjugated to a wide range of biologics, including full-length monoclonal antibodies, antibody fragments, enzymes, neurotrophic factors, and potentially oligonucleotides. The platform is designed to be agnostic to the cargo’s specific therapeutic function.
Q: What proof of concept do you have for your platform's efficacy? A: Our platform's design is grounded in robust, peer-reviewed RMT biology and builds upon publicly reported clinical successes from leaders in the field. We validate each shuttle through comprehensive in vitro BBB models and in vivo pharmacokinetic/pharmacodynamic studies in relevant animal models, generating concrete data on brain uptake, exposure, and target engagement for partner programs.
Q: What does the partnership and development process with Protheragen look like? A: We follow a collaborative, stage-gated workflow: It begins with a consultative phase to analyze your target and select the optimal shuttle strategy, followed by dedicated molecular engineering, in vitro validation, and in vivo proof-of-concept studies. We work as an extension of your team to de-risk development and generate the compelling data needed to advance your program.
Q: Is the platform suitable for diseases beyond neurodegeneration, like brain tumors? A: Yes. Our shuttles, particularly the IGF1R and TfR options, are highly relevant for CNS oncology. They are designed to enhance the delivery of chemotherapeutics, tumor-targeting antibodies, or immunomodulators across both the intact BBB and the compromised blood-tumor barrier, offering a targeted approach for conditions like glioblastoma.